Polypeptides Useful for Gene Editing and Methods of Use
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2019/068079, filed Dec 20, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,188,018 | Polypeptides Useful for Gene Editing and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence | ||
| US 12,655,426 | Polypeptides Useful for Gene Editing and Methods of Use In force · High confidence | Life Edit Therapeutics, Inc. | In force | High confidence | ||
| Application 18/826,746 | Polypeptides Useful for Gene Editing and Methods of Use Pending Not granted | LifeEDIT Therapeutics, Inc. | Pending | Not granted | ||
| Application 18/960,883 | Polypeptides Useful for Gene Editing and Methods of Use Pending Not granted | Life Edit Therapeutics, Inc. | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Lifeedit, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.